Market Cap
As of January 2, 2012: $766,108,000.00
Stock Chart
Sigma Pharmaceuticals - 30 Day Poll
Recent BLOGS About Sigma Pharma Add New
There are no blogs to display.
Latest Company News
|
Midday: Aus shares gain 0.5%
Finance News Network - Jan 24, 2012 Lifted with a positive lead from European markets the Australian share market has gained 0.5 per cent at noon. Stronger commodity prices overnight have boosted the miners and energy stocks as the sectors continues to absorb production reports today.
|
|
Sigma Pharmaceutical Limited Not To Pay FY 2011 Interim Dividend
Reuters Key Development - Sep 13, 2011 |
|
Sigma Pharmaceutical Limited Announces Ownership Interest Of Paradice Investment Management Pty Ltd
Reuters Key Development - May 19, 2011 |
|
Sigma Pharmaceutical Limited Sees FY 2011 EBIT Guidance At High End Of Prior Range
Reuters Key Development - Feb 27, 2011 |
|
Sigma Pharmaceutical Limited Signs Agreement For Sale Of Pharmaceuticals Division To Aspen Pharmacare Holdings Limited; Lowers FY 2011 EBIT Guidance
Reuters Key Development - Nov 22, 2010 |
|
Sigma Pharmaceutical Limited Announces Representative Proceedings
Reuters Key Development - Oct 31, 2010 |
Website
Videos related to Sigma Pharma
Company Profile
Sigma Pharmaceuticals Limited is engaged in the manufacturing, marketing and wholesale distribution of pharmaceutical products through the pharmacy and grocery channels and the provision of services to retail pharmacists.
The Company operates in three business segments: pharmaceuticals, healthcare and corporate. The pharmaceuticals segment includes contract manufacture for Australian and overseas pharmaceutical companies, and the manufacturing, selling and marketing of Sigma, Arrow, Herron and other pharmaceutical products.
The healthcare segment includes wholesale and distribution to pharmacy of prescription and over the counter products, management of banner groups and the development and provision of private label products.
The corporate segment includes corporate head office costs and all items associated with the New Zealand operations. In 2008 the Company completed the acquisition of Orphan Holdings Pty Limited.
The Company operates in three business segments: pharmaceuticals, healthcare and corporate. The pharmaceuticals segment includes contract manufacture for Australian and overseas pharmaceutical companies, and the manufacturing, selling and marketing of Sigma, Arrow, Herron and other pharmaceutical products.
The healthcare segment includes wholesale and distribution to pharmacy of prescription and over the counter products, management of banner groups and the development and provision of private label products.
The corporate segment includes corporate head office costs and all items associated with the New Zealand operations. In 2008 the Company completed the acquisition of Orphan Holdings Pty Limited.
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use
